These analyses hold immense potential to advance our knowledge of chronic lung diseases and drive the development of innovative treatments and drugs (e.g., HDAC and DNMT inhibitors, CRISPR-based epigenetic editing) (Figure 2). Here, HDAC9 is linked to chronic lung disease.